S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
OTCMKTS:ASPCF

Acerus Pharmaceuticals Stock Forecast, Price & News

$0.03
+0.01 (+42.18%)
(As of 01/14/2022 01:07 PM ET)
Add
Compare
Today's Range
$0.03
$0.03
50-Day Range
$0.02
$0.03
52-Week Range
$0.02
$0.07
Volume
155,700 shs
Average Volume
81,838 shs
Market Capitalization
$46.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.23
30 days | 90 days | 365 days | Advanced Chart
Receive ASPCF News and Ratings via Email

Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Acerus Pharmaceuticals logo

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men's health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ASPCF
CIK
N/A
Employees
147,000
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.09 million

Profitability

Net Income
$-24.42 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares
1,537,588,000
Free Float
N/A
Market Cap
$46.13 million
Optionable
Not Optionable

Company Calendar

Today
1/17/2022
Next Earnings (Estimated)
3/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Acerus Pharmaceuticals (OTCMKTS:ASPCF) Frequently Asked Questions

How has Acerus Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Acerus Pharmaceuticals' stock was trading at $0.0380 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ASPCF shares have decreased by 21.1% and is now trading at $0.03.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Acerus Pharmaceuticals?

Acerus Pharmaceuticals saw a drop in short interest in December. As of December 31st, there was short interest totaling 800 shares, a drop of 97.2% from the December 15th total of 28,400 shares. Based on an average trading volume of 11,900 shares, the days-to-cover ratio is presently 0.1 days.
View Acerus Pharmaceuticals' Short Interest
.

When is Acerus Pharmaceuticals' next earnings date?

Acerus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 9th 2022.
View our earnings forecast for Acerus Pharmaceuticals
.

Who are Acerus Pharmaceuticals' key executives?

Acerus Pharmaceuticals' management team includes the following people:
  • Edward Gudaitis, President, CEO & Non-Independent Director
  • Bob Motz, Chief Financial Officer
  • Christopher Sorli, Chief Medical Officer
  • Philippe Savard, Secretary, Vice President & General Counsel
  • Kevin Hickey, Senior Vice President-US Commercial

What is Acerus Pharmaceuticals' stock symbol?

Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ASPCF."

How do I buy shares of Acerus Pharmaceuticals?

Shares of ASPCF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Acerus Pharmaceuticals' stock price today?

One share of ASPCF stock can currently be purchased for approximately $0.03.

How much money does Acerus Pharmaceuticals make?

Acerus Pharmaceuticals has a market capitalization of $46.13 million and generates $1.09 million in revenue each year. The company earns $-24.42 million in net income (profit) each year or ($0.02) on an earnings per share basis.

How many employees does Acerus Pharmaceuticals have?

Acerus Pharmaceuticals employs 147,000 workers across the globe.

What is Acerus Pharmaceuticals' official website?

The official website for Acerus Pharmaceuticals is www.aceruspharma.com.

Where are Acerus Pharmaceuticals' headquarters?

Acerus Pharmaceuticals is headquartered at 2486 Dunwin Drive, Mississauga A6, L5L 1J9.

How can I contact Acerus Pharmaceuticals?

Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The company can be reached via phone at (416) 679-0771, via email at [email protected], or via fax at 905-569-1809.


This page was last updated on 1/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.